Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468767 · ClinicalTrials.gov registry record · Phase 3
Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation, sponsored by Advanz Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 356
- Enrollment target
- 20
- Study locations
NCT00468767 is a Phase 3 study of Atrial Fibrillation that has completed, run by Advanz Pharma. The registered enrollment target is 356 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00468767, a Phase 3 study of Atrial Fibrillation, has completed, sponsored by Advanz Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 356 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm.
Conditions Studied
Interventions
- DRUG Vernakalant Injection 20 mg/mL
Study Locations (20)
Alberta
- Heart Health Institute, Rockyview General Hospital - Calgary
- University of Calgary - Calgary
- University of Alberta Hospital - Edmonton
Ontario
- Hamilton Health Sciences, Hamilton General Hospital - Hamilton
- Ottawa Hospitals (Civic & General) - Ottawa
- Sunnybrook Health Sciences Centre, Emergency Medicine Research Program - Toronto
California
- University of California - Los Angeles
- Regional Cardiology Associates - Sacramento
Florida
- Florida Heart Institute - Orlando
- James Haley VA Hospital - Tampa
Virginia
- Medical College of Virginia - Richmond
- McGuire VA Medical Center - Richmond
Quebec
- Institut de Cardiologie de Montreal - Montreal
- Hopital Notre-Dame du CHUM - Montreal
Massachusetts
- Cardiac Arrhythmia Service, Massachusetts General Hospital - Boston
Michigan
- Thoracic and Cardiovascular Institute - Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2003-08 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00468767
The ClinicalTrials.gov registry entry for NCT00468767 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The listed sponsor is Advanz Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Vernakalant Injection 20 mg/mL is the first listed.
NCT00468767 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Alberta, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT00468767 about?
NCT00468767 is a clinical study titled "Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation". This study is being conducted to demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm.
What is the current status of trial NCT00468767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 356 participants. The study started on 2003-08. Estimated completion is 2004-11.
What conditions does trial NCT00468767 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT00468767?
The interventions under investigation include: Vernakalant Injection 20 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00468767?
This trial is sponsored by Advanz Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00468767 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Michigan, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.